Effects of lumacaftor/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial
by Stahl, Mirjam (Author)
, Roehmel, Jobst (Author)
, Eichinger, Monika (Author)
, Doellinger, Felix (Author)
, Naehrlich, Lutz (Author)
, Kopp, Matthias V. (Author)
, Dittrich, Anna-Maria (Author)
, Lee, Christopher (Author)
, Sommerburg, Olaf (Author)
, Tian, Simon (Author)
, Xu, Tu (Author)
, Wu, Pan (Author)
, Joshi, Aniket (Author)
, Ray, Partha (Author)
, Duncan, Margaret E. (Author)
, Wielpütz, Mark Oliver (Author)
, Mall, Marcus A. (Author)
,
Call Number:
Loading…
Located:
Loading…
Article (Journal)
Online Resource